Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Shire plc (SHPG - Analyst Report) announced positive top-line results from two phase III studies on attention deficit and hyperactivity disorder (ADHD) drug Vyvanse for additional indications.

We note that Shire is developing Vyvanse for additional indications such as the treatment of negative symptoms of schizophrenia and binge eating disorder (BED).

The two randomized phase III studies were conducted to evaluate the safety and efficacy of Vyvanse compared to placebo in adults suffering from BED. The results from the study showed that Vyvanse was statistically superior to placebo on the primary efficacy analysis while maintaining a safety profile.

Consequently, Shire plans to submit a Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration for the treatment of BED in adults (ages 18 to 55) by the third quarter of 2014.

We are also encouraged by Shire’s efforts for the label expansion of Vyvanse. We remind investors that Shire holds a strong position in the ADHD market driven by key drugs like Vyvanse, Intuniv and Adderall XR.

Shire’s growth engine is Vyvanse, which accounted for approximately 24.4% of total revenues in the first nine months of 2013. Shire is now focused on exploring Vyvanse outside the U.S. Vyvanse (under trade name Elvanse) was approved in the EU in Dec 2012. Shire plans to capture 75% of the total EU market by 2014.

Shire currently carries a Zacks Rank #1 (Strong Buy). Other stocks that currently look attractive include Forest Laboratories (FRX - Analyst Report), Salix Pharmaceuticals (SLXP - Analyst Report) and NPS Pharmaceuticals, Inc. (NPSP - Analyst Report). All three carry a Zacks Rank #2 (Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%